Director at Assembly Biosciences (NASDAQ: ASMB) receives 8,000 options

Q: What is the exercise price and expiration date of Anthony E. Altig’s ASMB options?

The granted stock options carry an exercise price of $24.11 per share and expire on June 4, 2036 . Altig can choose to exercise the options before expiration once they vest, subject to the company’s plan terms.

Q: Is Anthony E. Altig’s ASMB Form 4 transaction a stock purchase or a compensation grant?

The Form 4 shows a grant of stock options to Anthony E. Altig as compensation, coded as a grant/award acquisition. It is not an open-market stock purchase or sale, but a right to buy 8,000 shares at a fixed price later.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Assembly Biosciences, Inc. reported that director Anthony E. Altig received a grant of stock options to acquire 8,000 shares of Common Stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036.

These options vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Altig holds stock options for 8,000 underlying shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ALTIG ANTHONY E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	8,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 8,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 8,000 options Exercise price: $24.11 per share Expiration date: June 4, 2036 +2 more

5 metrics

Options granted 8,000 options Stock Option (right to buy) granted to director

Exercise price $24.11 per share Conversion/exercise price of granted stock options

Expiration date June 4, 2036 Option expiration for granted stock options

Underlying shares 8,000 shares Common Stock underlying the stock options

Post-grant derivative holdings 8,000 options Total derivative securities following transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Common Stock, vest

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vest financial

"The stock options vest, assuming continuous service, upon the earlier of"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALTIG ANTHONY E

(Last)

(First)

(Middle)

C/O ASSEMBLY BIOSCIENCES, INC.

TWO TOWER PLACE, 7TH FLOOR

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$24.11	06/04/2026		A		8,000		⁽¹⁾	06/04/2036	Common Stock	8,000	$0	8,000	D

Explanation of Responses:

1. Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ John O. Gunderson, as Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Assembly Biosciences (ASMB) disclose for Anthony E. Altig?

Assembly Biosciences (ASMB) disclosed that director Anthony E. Altig received a grant of stock options for 8,000 shares of Common Stock. These options are part of his compensation and give him the right to buy shares at a fixed exercise price in the future.

How many stock options were granted to Anthony E. Altig at Assembly Biosciences (ASMB)?

Anthony E. Altig was granted options on 8,000 shares of Assembly Biosciences (ASMB) Common Stock. This derivative award represents a future right to purchase shares, rather than an immediate stock purchase or sale in the open market.

What is the exercise price and expiration date of Anthony E. Altig’s ASMB options?

The granted stock options carry an exercise price of $24.11 per share and expire on June 4, 2036. Altig can choose to exercise the options before expiration once they vest, subject to the company’s plan terms.

When do Anthony E. Altig’s Assembly Biosciences (ASMB) stock options vest?

The options vest, assuming continuous service, on the earlier of June 4, 2027 or the date of Assembly Biosciences’ 2027 annual meeting of stockholders. Vesting determines when Altig can begin exercising these stock options.

Is Anthony E. Altig’s ASMB Form 4 transaction a stock purchase or a compensation grant?

The Form 4 shows a grant of stock options to Anthony E. Altig as compensation, coded as a grant/award acquisition. It is not an open-market stock purchase or sale, but a right to buy 8,000 shares at a fixed price later.